

**SENATE**  
**STATE OF MINNESOTA**  
**NINETIETH SESSION**

**S.F. No. 2786**

(SENATE AUTHORS: HAYDEN, Isaacson, Wiklund, Miller and Benson)

DATE	D-PG	OFFICIAL STATUS
03/01/2018	6227	Introduction and first reading Referred to Health and Human Services Finance and Policy
03/08/2018	6371	Author added Isaacson
03/12/2018	6431	Author added Wiklund
03/19/2018	6793	Author added Miller
03/22/2018	6930	Author added Benson
03/27/2018	7018a	Comm report: To pass as amended and re-refer to State Government Finance and Policy and Elections
03/29/2018	7116	Comm report: To pass and re-referred to Higher Education Finance and Policy See SF3656, Art. 35, Sec. 11 See SF799, Sec. 1, Sub. 2(a)

1.1 A bill for an act

1.2 relating to health; establishing an advisory council on rare diseases to advise the

1.3 commissioner of health on issues related to rare diseases; proposing coding for

1.4 new law in Minnesota Statutes, chapter 137.

1.5 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

1.6 Section 1. **[137.68] ADVISORY COUNCIL ON RARE DISEASES.**

1.7 Subdivision 1. **Establishment.** The Board of Regents of the University of Minnesota is

1.8 requested to establish an advisory council on rare diseases to provide advice on research,

1.9 diagnosis, treatment, and education related to rare diseases. For purposes of this section,

1.10 "rare disease" has the meaning given in United States Code, title 21, section 360bb. The

1.11 council shall be called the Chloe Barnes Advisory Council on Rare Diseases.

1.12 Subd. 2. **Membership.** (a) The advisory council may consist of public members appointed

1.13 by the Board of Regents or a designee according to paragraph (b) and four members of the

1.14 legislature appointed according to paragraph (c).

1.15 (b) The Board of Regents or a designee is requested to appoint the following public

1.16 members:

1.17 (1) three physicians licensed and practicing in the state with experience researching,

1.18 diagnosing, or treating rare diseases;

1.19 (2) one registered nurse or advanced practice registered nurse licensed and practicing

1.20 in the state with experience treating rare diseases;

1.21 (3) at least two hospital administrators, or their designees, from hospitals in the state

1.22 that provide care to persons diagnosed with a rare disease. One administrator or designee

2.1 appointed under this clause must represent a hospital in which the scope of service focuses  
2.2 on rare diseases of pediatric patients;

2.3 (4) three persons age 18 or older who either have a rare disease or are a caregiver of a  
2.4 person with a rare disease;

2.5 (5) a representative of a rare disease patient organization that operates in the state;

2.6 (6) a social worker with experience providing services to persons diagnosed with a rare  
2.7 disease;

2.8 (7) a pharmacist with experience with drugs used to treat rare diseases;

2.9 (8) a representative of the biotechnology industry;

2.10 (9) a representative of health plan companies; and

2.11 (10) other public members, who may serve on an ad hoc basis.

2.12 (c) The advisory council shall include two members of the senate, one appointed by the  
2.13 majority leader and one appointed by the minority leader, and two members of the house  
2.14 of representatives, one appointed by the speaker of the house and one appointed by the  
2.15 minority leader.

2.16 (d) The commissioner of health or a designee, a representative of Mayo Medical School,  
2.17 and a representative of the University of Minnesota Medical School shall serve as ex officio,  
2.18 nonvoting members of the advisory council.

2.19 (e) Initial appointments to the advisory council shall be made no later than July 1, 2018.  
2.20 Members appointed according to paragraph (b) shall serve for a term of three years, except  
2.21 that the initial members appointed according to paragraph (b) shall have an initial term of  
2.22 two, three, or four years determined by lot by the chairperson. Members appointed according  
2.23 to paragraph (b) shall serve until their successors have been appointed.

2.24 Subd. 3. **Meetings.** The Board of Regents or a designee is requested to convene the first  
2.25 meeting of the advisory council no later than September 1, 2018. The advisory council shall  
2.26 meet at the call of the chairperson or at the request of a majority of advisory council members.

2.27 Subd. 4. **Duties.** The advisory council's duties may include, but are not limited to:

2.28 (1) developing, in conjunction with the state's medical schools, public health schools,  
2.29 and hospitals in the state that provide care to persons diagnosed with a rare disease, resources  
2.30 or recommendations relating to the quality of and access to treatment and services in the  
2.31 state for persons with rare disease, including but not limited to:

3.1 (i) a list of existing publicly accessible resources on the research, diagnosis, treatment,  
3.2 and education relating to rare diseases;

3.3 (ii) identified best practices for rare disease care implemented in other states and at the  
3.4 national and international levels that will improve rare disease care in the state and seeking  
3.5 opportunities to partner with similar organizations in other states and counties;

3.6 (iii) identified problems faced by patients with a rare disease when changing health  
3.7 plans, including recommendations on how to remove obstacles faced by these patients to  
3.8 finding a new health plan and how to improve the ease and speed of finding a new health  
3.9 plan that meets the needs of patients with a rare disease; and

3.10 (iv) identified best practices to ensure health care providers are adequately informed of  
3.11 the most effective strategies for recognizing and treating rare diseases; and

3.12 (2) advising, consulting, and cooperating with the Department of Health, the Advisory  
3.13 Committee on Heritable and Congenital Disorders, and other agencies of state government  
3.14 in developing information and programs for the public and the health care community  
3.15 relating to the diagnosis, treatment, and awareness of rare diseases.

3.16 Subd. 5. **Conflict of interest.** Advisory council members are subject to the Board of  
3.17 Regents policy on conflicts of interest.

3.18 Subd. 6. **Annual report.** By January 1 of each year, beginning January 1, 2019, the  
3.19 advisory council shall report to the chairs and ranking minority members of the legislative  
3.20 committees with jurisdiction over higher education and health care policy on the advisory  
3.21 council's activities under subdivision 4 and other issues on which the advisory council may  
3.22 choose to report.

3.23 **EFFECTIVE DATE.** This section is effective the day following final enactment.